Skip to main content
logo
Intra-Cellular Therapies, Inc. (ITCI)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025

Intra-Cellular Therapies Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
680.85680.85464.37250.3183.822.81
Revenue Growth
46.62%46.62%85.52%198.69%267.35%37537.14%
Gross Profit
387.77387.77250.4895.16-13.08-44.86
Operating Income
-116.72-116.72-159.38-263.63-285.69-231.23
Net Income
-74.68-74.68-139.67-256.26-284.13-227.01
Earnings Per Share
-0.72-0.72-1.46-2.72-3.50-3.23
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
1,0011,001497.94591.91412.33657.45
Total Debt
16.9816.9816.9420.0425.4129.14
Net Cash (Debt)
984.09984.09481571.86386.93628.31
Net Cash Growth
104.59%104.59%-15.89%47.80%-38.42%212.80%
Net Cash Per Share
9.549.545.026.084.768.93

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-73.18-73.18-124.2-270.19-259.54-230.07
Capital Expenditures
-0.32-0.32-0.27-0.78-0.33-0.27
Free Cash Flow
-73.5-73.5-124.47-270.96-259.87-230.34
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
56.95%56.95%53.94%38.02%-15.60%-196.66%
Operating Margin
-17.14%-17.14%-34.32%-105.32%-340.90%-1013.58%
Pretax Margin
-10.90%-10.90%-29.94%-102.37%-339.03%-995.01%
Profit Margin
-10.97%-10.97%-30.08%-102.37%-339.04%-995.07%
FCF Margin
-10.79%-10.79%-26.80%-108.25%-310.10%-1009.69%

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
19.9713.0114.8420.0250.88111.74